Workforce Development, Diversity, & Inclusion at BIO

In June 2017, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry.  Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry.  The Committee is chaired by Helen Torley, President & CEO of Halozyme, who succeeded Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.

Our mission is to create a more globally competitive biotechnology industry by promoting and enhancing workforce development, diversity, and inclusion.

Learn who serves on BIO's WDDI committee.

Below are a list of resources available.